Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).
Type:
Grant
Filed:
October 8, 2013
Date of Patent:
March 28, 2017
Assignee:
PROTHENA BIOSCIENCES LIMITED
Inventors:
Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar
Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.
Abstract: The invention provides anti-MCAM antibodies that inhibit the ability of human MCAM to bind a laminin alpha-4 chain. The invention also provides pharmaceutical compositions, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer.
Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.
Type:
Grant
Filed:
September 9, 2013
Date of Patent:
September 20, 2016
Assignee:
PROTHENA BIOSCIENCES LIMITED
Inventors:
Kenneth Flanagan, Jeanne Baker, Theodore A. Yednock
Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
Type:
Application
Filed:
March 12, 2014
Publication date:
February 4, 2016
Applicant:
Prothena Biosciences Limited
Inventors:
Peter Seubert, Philip James Dolan, III, Yue Liu, Robin Barbour
Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.
Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.
Abstract: The invention provides monoclonal antibody 5Cl and related antibodies. The 5Cl antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).
Type:
Application
Filed:
October 8, 2013
Publication date:
September 17, 2015
Applicant:
PROTHENA BIOSCIENCES LIMITED
Inventors:
Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar
Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
Type:
Grant
Filed:
February 23, 2007
Date of Patent:
May 19, 2015
Assignee:
Prothena Biosciences Limited
Inventors:
Dale B. Schenk, Eliezar Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Kate Dora Games